Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Angal S is a fixed-dose combination topical spray containing the antiseptic chlorhexidine gluconate and the local anesthetic lidocaine hydrochloride. Developed by Sandoz (Lek), it is used for the symptomatic treatment of inflammatory and infectious diseases of the oral cavity and pharynx, such as sore throat, pharyngitis, and gingivitis. Chlorhexidine provides broad-spectrum antimicrobial activity by disrupting bacterial and fungal cell membranes, while lidocaine acts as a sodium channel blocker to provide rapid, localized pain relief. The 'S' in the name typically denotes the spray formulation, and variants may include flavoring agents such as menthol or lemon.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine + lidocaine.